How Will PainChek Capitalise on FDA Clearance Amid Rising Losses?

Financial Performance and Loss Expansion

PainChek Limited has reported a net loss of AUD 4.7 million for the half-year ended 31 December 2025, a significant increase from the AUD 3.16 million loss recorded in the same period last year. Revenue from continuing operations rose modestly by 5% to AUD 1.73 million, reflecting steady growth in subscription and service income. However, the company’s operating expenses surged, driven by heightened marketing and business development efforts, as well as sustained investment in research and development.

Regulatory Breakthrough Opens US Market

The standout highlight of the period was PainChek’s receipt of FDA De Novo clearance for its Adult App in October 2025. This regulatory milestone positions PainChek as the first and only provider of a regulated medical device for pain assessment in US long-term care settings for individuals with moderate to severe dementia. The clearance unlocks access to an estimated AUD 175 million annual market in US long-term care, with potential expansion into home care and hospital sectors through future regulatory pathways.

Moreover, independent legal advice confirmed that PainChek qualifies for reimbursement under the US Centers for Medicare & Medicaid Services’ Remote Therapeutic Monitoring (RTM) guidelines. This eligibility opens a pathway to a rapidly growing US RTM market projected to reach USD 3 billion by 2030, encompassing both long-term care and home health sectors.

Commercial Progress and Customer Base Expansion

PainChek’s global footprint continues to expand, with 75,590 paying implementations generating an annual recurring revenue of AUD 3.7 million, up 12% from the previous period. Customer retention remains robust at 85%, with a significant portion of contracts extending beyond three years, underscoring strong client loyalty. In the US and Canada, the company has established initial skilled nursing facility customers and is building a sales pipeline supported by a dedicated North American team.

In Australia, New Zealand, and the UK, PainChek holds licenses covering over 110,000 beds combined, capturing over 30% market share in ANZ and 10% in the UK aged care market. Collaborations with Digital Health Innovation Scotland and ongoing pilots in hospital settings aim to broaden adoption beyond aged care.

Infant App and Product Development Initiatives

The PainChek Infant App, launched in Australia during the period, remains in early commercialisation with modest subscription uptake. The company is refining its pricing and onboarding processes based on initial consumer feedback and advancing product updates incorporating clinical partnerships. Concurrently, R&D efforts continue on new prototypes including a vocalisation-based infant pain assessment and a toddler app extension.

Capital Structure and Governance Updates

To support its growth ambitions, PainChek completed a 1-for-10 share consolidation and raised capital through a placement, strengthening its cash position to AUD 4.78 million at period end. The company also granted performance rights to its CEO and non-executive directors as part of remuneration arrangements, aligning incentives with future share price performance and company milestones.

Despite the progress, the financial statements highlight material uncertainty regarding the company’s ability to continue as a going concern, reflecting ongoing losses and dependence on successful commercialisation and funding. The directors remain confident, citing recent capital raises and strategic advances.